AZ stock leaps on Seroquel hearing news

Color AstraZeneca hopeful. A U.S. court hearing over Seroquel's patents has been bumped forward to today from June 4, boosting speculation that the drugmaker might just come out on top in the high-stakes case. (It hasn't hurt AstraZeneca's stock, either.) Today's hearing is to consider AstraZeneca's request for summary judgment in the case; a decision might not be handed down today, though.

Back in February, AstraZeneca announced it would seek an early decision in its Seroquel patent fight with generics giant Teva Pharmaceutical Industries. At risk: AstraZeneca's $4 billion antipsychotic drug, the company's second-biggest seller, accounting for an expected 28 percent of 2008 earnings. If the judge decides not to grant summary judgment, the Seroquel fight is set to go to trial in August.

- read the article at MarketWatch
- see the Forbes piece
- check out The Guardian's take

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.